The United States Rheumatic Diseases Therapeutics Market
The United States Rheumatic Diseases Therapeutics Market
Changes on the Horizon with Novel Oral Therapies for Musculoskeletal Indications
28-Aug-2012
North America
$9,000.00
Special Price $6,750.00 save 25 %
Description
This research service covers the therapeutics for rheumatic diseases market in the United States from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS); background standard of care therapies are not covered in this study. Included in the study are products already on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by disease indication: RA, PsA, and AS.
Table of Contents
Analysis of the United States Rheumatic Diseases Therapeutics Market
- Executive Summary and Market Overview
Analysis of the Total Rheumatic Diseases Therapeutics Market
- Drivers and Restraints
- Forecasts and Trends
- Demand Analysis
- Market Share and Competitive Analysis
Analysis of the Rheumatoid Arthritis Segment
- Segment Breakdown and Market Engineering Measurements
- Patient Forecast
- Pricing Trends and Forecast
- Revenue Forecast
- Market Share Analysis
Analysis of the Psoriatic Arthritis Segment
- Segment Breakdown and Market Engineering Measurements
- Patient Forecast
- Pricing Trends and Forecast
- Revenue Forecast
- Market Share Analysis
Analysis of the Ankylosing Spondylitis Segment
- Segment Breakdown and Market Engineering Measurements
- Patient Forecast
- Pricing Trends and Forecast
- Revenue Forecast
- Market Share Analysis
The Last Word
- Summary and Conclusions
Appendix
- Appendix
No Index | Yes |
---|---|
Podcast | No |
Author | Deborah Toscano |
Industries | Healthcare |
WIP Number | NAF0-01-00-00-00 |
Is Prebook | No |